Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-RESERP vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
50-100 hours (terminal); prolonged in renal impairment, leading to accumulation on repeated dosing.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hydrochlorothiazide is not extensively metabolized; it is excreted unchanged in urine. Reserpine is extensively metabolized in the liver by hydrolysis and conjugation.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 30-40% as unchanged reserpine; biliary/fecal: 60-70% as metabolites.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
96% bound to albumin and alpha1-acid glycoprotein.
~90%, primarily to albumin
1.5-2.5 L/kg; extensive tissue distribution with high affinity for adrenergic neurons.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 50-60% (first-pass metabolism); IM: ~100%.
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated if e GFR <30 m L/min/1.73m² due to HCTZ ineffectiveness. For GFR 30-50 m L/min: reduce HCTZ to 12.5-25 mg daily; reserpine unchanged. Monitor serum creatinine and electrolytes. Not recommended for anuric patients.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce HCTZ by 25-50% (start at 12.5 mg) due to risk of electrolyte imbalance; reserpine: use lowest effective dose (0.125 mg) and monitor for encephalopathy. Child-Pugh C: avoid HCTZ; reserpine contraindicated due to risk of hepatic coma.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not approved for pediatric use. Limited data: HCTZ 1-2 mg/kg/day orally once or divided; max 50 mg/day. Reserpine 0.01-0.02 mg/kg/day in 1-2 doses; max 0.25 mg/day. Monitor growth, electrolytes, and blood pressure closely in children.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at half the adult dose: HCTZ 12.5 mg orally daily; reserpine 0.05-0.1 mg daily. Titrate slowly (every 2-4 weeks). Monitor for orthostatic hypotension, electrolyte disturbances, depression (reserpine), and dehydration. Avoid in frail elderly due to increased fall risk.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Reserpine may cause mental depression, especially in patients with a history of depression. Risks are dose-related and may persist after discontinuation. Use with caution or avoid in patients with a history of depression.
None
May cause depression with suicidal risk (reserpine).,May cause electrolyte imbalances (hypokalemia, hyponatremia) due to hydrochlorothiazide.,May increase serum uric acid and precipitate gout.,May cause orthostatic hypotension and bradycardia.,Use cautiously in patients with renal impairment or hepatic disease.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to hydrochlorothiazide, reserpine, or sulfonamide derivatives.,History of depression (especially with reserpine).,Active peptic ulcer or ulcerative colitis (reserpine).,Electroconvulsive therapy (within 1 week).,Severe renal impairment (anuria) or severe hepatic disease.,Pregnancy (especially in second and third trimesters; avoid use).
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-sodium foods to reduce blood pressure; limit alcohol consumption. Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats, fermented foods) as reserpine may potentiate pressor response; however, risk is low with reserpine compared to MAOIs. Maintain potassium-rich diet if hypokalemia risk exists (e.g., bananas, oranges, spinach).
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Reserpine crosses the placenta. First trimester: limited human data but animal studies suggest risk; consider alternative if possible. Second/third trimester: may cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion. Avoid in preeclampsia due to risk of placental hypoperfusion. Risk category C.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Reserpine is excreted into breast milk. M/P ratio approximately 1.6. Potential for infant bradycardia, nasal congestion, and lethargy. Contraindicated in nursing mothers due to risks.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No specific dose adjustments based on pharmacokinetic changes in pregnancy. Use lowest effective dose to minimize fetal risk.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Hydro-Reserp combines hydrochlorothiazide and reserpine; reserpine depletes catecholamines, which may cause depression and sedation. Monitor for orthostatic hypotension and electrolyte imbalances. Avoid in patients with history of depression or peptic ulcer disease. Use with caution in patients with renal impairment.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take this medication exactly as prescribed; do not stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery if affected.,Stand up slowly from sitting or lying down to prevent falls.,Report any signs of depression, unusual mood changes, or slow heartbeat.,Avoid excessive sun exposure; may increase sensitivity to sunlight.,Do not use alcohol while taking this medication.,Monitor blood pressure regularly and keep follow-up appointments.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-RESERP vs ALDORIL 15, answered by our medical review team.
HYDRO-RESERP is a Antihypertensive Combination that works by Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-RESERP and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-RESERP is: HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-RESERP and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-RESERP is classified as Category C. Reserpine crosses the placenta. First trimester: limited human data but animal studies suggest risk; consider alternative if possible. Second/third trimester: may cause neonatal re. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.